Falko Friedrichs: Thank you very much. Good morning. A few follow-ups, please. Firstly, Abhijit, did I understand your comment on order intake correct that Q4 should still be negative but less negative than in Q3? Then secondly, could you update us on the number of patients in the census register, those people that could potentially sue you, and how many of those have found themselves a lawyer at this point? And then the third question, could you just give us a few examples of the countries where you have returned to the market with your sleep and respiratory care products? Thank you.
Abhijit Bhattacharya: Yeah. So, on Q4, we have said it’s going to be a significant improvement on the minus 9%. Now whether that is going to be negative or positive, given all the uncertainties, we are not speculating on that at the moment, but it will be a substantial improvement on the minus 9% that we had in Q3.
Roy Jakobs: On the census registry, so currently, Falko, we have 54,000 people registered. But out of those, only 670 currently are in the process with a judge — with a lawyer in terms of claiming anything. So, those are the two numbers, which are the latest to date. And then on the third one, in return to market, which countries are you selling, this is starting across the globe. So, Japan is an important market for us, of course, that we are very strong in. We have a full suite. We also started to re-enter in China. We have, Australia, Latin America, but also in the EU. So, actually, we are working now through the process with every regulator across the globe to kind of go through and actually we are getting a very positive support in — in many of the markers and that’s also where we see us coming back into.
Falko Friedrichs: Okay, thank you.
Operator: Thank you. That was the final question. Mr. Jakobs, please continue with any points you would like to raise.
Roy Jakobs: Yeah, thank you all for great questioning and the dialog we had around it. So, just to close. So what you have heard us discuss is a very strong performance and a strong performance improvement this year so far. We had a strong third quarter where we delivered 11% growth doubling our profit and strong cash flow. It was a fourth quarter of growth that you have seen, and that actually really increases our confidence to also increase the guidance second time this year towards a strong close of this year, which would bring us ahead of the first-year plan that we announced in January. It also gives us confidence in the execution of the second and third year of our plan, as we see the actions we are taking really having an impact both on supporting strong sales, supporting also margin improvement, and productivity, you see dialing back into our profitability step up.
So, that, with the actions on order intake, will give us a lot of confidence in continuing to work on our trajectory to bring Philips back where it belongs. Thank you so much for your attention and looking forward to connect with you soon.
Operator: Thank you. This concludes the Royal Philips Third Quarter 2023 Results Conference Call on Monday, October 23, 2023. Thank you for participating. You may now disconnect.
